Flexibility And Capability In Pre-Filled Syringes: The Future Of PFS
Pre-filled syringes (PFS) have been rising in popularity and utility for some time, but COVID-19 has created fertile ground for something of an acceleration in adoption.
The pandemic’s direct and indirect impact on drug development, manufacturing, and healthcare systems are feeding a shift to PFS that shows no sign of stopping – in fact, it looks to heat up considerably in the coming months.
In this white paper, we outline the inherent benefits of PFS and how they relate to the delivery of drugs such as biologics and vaccines, how SARS-CoV-2 could be fueling an explosive increase in PFS demand, and finally explore how a partnership with a flexible CDMO is the key to success.
KEY POINTS
- PFS is a growing market, estimated to be worth $9.7bn in the next few years.1
- Benefits include fewer dosing errors and needle stick injuries (NSI), improved adherence and better self-management.
- COVID-19 vaccines are currently being manufactured in needle and vial presentations, contributing to a worldwide shortage of glass vials and production capacity.
- As drug manufacturers pivot to PFS in response to the shortage, they are embracing the additional benefits.
- PFS is well-recognized as the primary delivery system for vaccines. It means developers and manufacturers of all stripes need to prepare for COVID-19 vaccines to move to PFS.2
- Partnership with an experienced CDMO who has the flexibility and capability to support projects is key to staying ahead of the curve.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.